BYSI BeyondSpring

BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference

BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference

NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that management will present and participate in the R.W. Baird’s 2023 Global Healthcare Conference, taking place on September 12 to 13, 2023 in New York City.

The presentation will be accessible on BeyondSpring’s website on the  page following the conclusion of the conference.

About BeyondSpring

(NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring’s subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration with Eli Lilly. Learn more by visiting, and follow us on and.

Investor Contact:

Media Contact:



EN
07/09/2023

Underlying

BYSIBeyondSpring

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BeyondSpring

 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showin...

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions.Biomarker analysis linked Plinabulin’s mechanism to GEF-H1–dependent dendritic cell maturation, offering the potential to pre-select patients at baseline and predict clinical respo...

July 7, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pem...

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it presented int...

June 3, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at , taking place on May 30 through June 3 in Chicago, IL. ​​Presentation de...

May 28, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides...

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapySEED’s first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism targeted cancer indication-Ewing Sarcoma, remains on track for IND filing mid‑2025 FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI), a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutic...

May 12, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Files 2024 Annual Report on Form 10-K

BeyondSpring Files 2024 Annual Report on Form 10-K FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”) on March 27, 2025. The annual report on Form 10-K, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at and on the Company...

March 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch